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Abstract
Background—A previous study showed
that the glucocorticoid dexamethasone,
at doses of 100 µg/kg and above, inhibited
leucocyte adhesion to rat mesenteric
postcapillary venules activated with in-
terleukin 1â (IL-1â), as assessed by video-
microscopy.
Aims—To identify whether the adhesion
molecule, intercellular adhesion molecule
1 (ICAM-1), or the chemokine KC could
be targeted by the steroid to mediate its
antiadhesive eVect.
Methods—Rat mesenteries were treated
with IL-1â (20 ng intraperitoneally) and
the extent of leucocyte adhesion measured
at two and four hours using intravital
microscopy. Rats were treated with dexa-
methasone, and passively immunised
against ICAM-1 or KC. Endogenous ex-
pression of these two mediators was
validated by immunohistochemistry,
ELISA, and the injection of specific radio-
labelled antibodies.
Results—Dexamethasone greatly reduced
IL-1â induced leucocyte adhesion, en-
dothelial expression of ICAM-1 in the post-
capillary venule, and release of the mast
cell derived chemokine KC. Injection of
specific antibodies to the latter mediators
was also extremely eVective in downregu-
lating (>80%) IL-1â induced leucocyte
adhesion.
Conclusions—Induction by IL-1â of endo-
genous ICAM-1 and KC contributes to leu-
cocyte adhesion to inflamed mesenteric
vessels. Without excluding other possible
mediators, these data clearly show that
dexamethasone interferes with ICAM-1
expression and KC release frommast cells,
resulting in suppression of leucocyte accu-
mulation in the bowel wall, which is a
prominent feature of several gastro-
intestinal pathologies.
(Gut 1999;45:705–712)
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Glucocorticoid hormones are potent therapeu-
tic tools in the management of inflammatory
pathologies of the gastrointestinal tract, includ-
ing inflammatory bowel disease. These and
related pathologies are characterised by the
presence of a prominent leucocyte infiltrate in
the bowel wall. As glucocorticoid hormones
show a potent ability to inhibit and suppress
leucocyte accumulation into inflamed tissues,1 2
an eVect on this component of the host inflam-
matory response may underline their therapeu-
tic eYcacy.
The accumulation of leucocytes in injured
tissues is the result of a series of concerted
events regulated by adhesion molecules ex-
pressed both on the circulating leucocyte and
the vascular endothelium, and by the presence
of specific leucocyte activators (chemokines).3 4
Videomicroscopy has shown that leucocytes
roll on an inflamed vascular endothelium; this
leads to firm adhesion and may be followed by
emigration through the endothelial wall into
the tissue.5 The three events of rolling,
adhesion, and emigration are linked both func-
tionally and temporally.6 The initial rolling is
mediated by selectins that are expressed on
leucocytes and the endothelium of the postcap-
illary venule; leucocyte firm adhesion is often
sustained by â2 integrins exposed on the leuco-
cyte plasma membrane and their counter
ligands, which include members of the immu-
noglobulin supergene family such as intercellu-
lar adhesion molecule 1 (ICAM-1).3 7 Chemo-
kines are an important class of mediators which
can show selectivity for diVerent leucocyte
subsets. Expression of specific chemokines can
explain the selective cell accumulation charac-
teristic of distinct pathologies. In particular, the
CXC chemokines are involved in the extravasa-
tion of neutrophils. The archetypal CXC
chemokine is interleukin (IL) 88; KC (also
known as cytokine induced neutrophil chem-
oattractant) is the major rat counterpart of
interleukin 8.9
Interleukin 1 is a multipotent cytokine able
to initiate the cascade of events listed above and
to lead to intense accumulation of blood borne
cells into injured tissues, including sections of
the gut.10 Indeed, IL-1 plays an important role
in experimental models of inflammatory bowel
disease11 12; this has been substantiated by
clinical studies.13 14
Using videomicroscopy we have shown that
if direct acting chemoattractants (such as
platelet activating factor or formylated pep-
tides) are superfused onto the microvascular
tissues of the rat mesentery to promote the
leucocyte-endothelium interaction, treatment
of animals with dexamethasone (DEX) aVects
selectively the leucocyte emigration process
(also referred to as diapedesis), but not the
rolling or adhesion processes.15 16 This eVect of
DEX seems to be due to increased amounts of
lipocortin 1 in the adherent leucocyte,17 with
consequent inhibition of the extent of cell
transendothelial passage.15 18 When indirect
leucocyte chemoattractants are used, such as
Abbreviations used in this paper: BSA, bovine
serum albumin; DEX, dexamethasone; ICAM,
intercellular adhesion molecule; IL, interleukin; PBS,
phosphate buVered saline.
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IL-1â, DEX is then also able to inhibit
leucocyte adhesion to rat mesenteric postcapil-
lary venules. However, doses of DEX in excess
of 100 µg/kg are required to observe this action
which maximally reaches 50% inhibition.16
In the present study we sought to identify
some of the molecular determinants responsible
for the antiadhesive eVect of DEX seen in
mesenteric postcapillary venules exposed to
IL-1â.We hypothesised that potential targets for
DEX action could be the adhesion molecule
ICAM-1 and the CXC chemokine KC; the syn-
thesis of both these mediators is induced by
IL-1â and is inhibited by DEX in vitro.19 20
Methods
ANIMALS
Male Sprague-Dawley rats (175–200 g body
weight) were purchased from Interfauna
(Huntingdon, UK) or from Charles River
(Saint Aubin les Elbeuf, France) and main-
tained on a standard chow pellet diet with tap
water ad libitum. All animals were housed for
one week on a 12 hour light-dark cycle for
acclimatisation prior to experimentation. For
intravital microscopy studies all animals were
starved for 24 hours prior to experimentation.
INTRAVITAL MICROSCOPY
The rat mesenteric preparation was set up as
described recently.16 Rats were injected intra-
peritoneally with 20 ng rat recombinant IL-1â
(generous gift of Dr RC Newton, Du-Pont
Merck,Wilmington, Delaware, USA) and were
left at liberty prior to experimentation. Control
animals received sterile saline alone (1 ml per
rat intraperitoneally). Particular care was taken
to observe the mesenteric vascular bed at
exactly two or four hours after injection of the
cytokine. Animals were anaesthetised with
Inactin (sodium thiopentobarbital 120 mg/kg
body weight intraperitoneally; RBI Natick,
Massachusetts, USA); the neck and abdominal
areas were gently shaved, and a tracheotomy
was performed to facilitate breathing during
experimentation. A midline abdominal incision
was made and a loop of the ileal mesentery was
exteriorised and superfused at a rate of 2
ml/min with warmed (37°C) bicarbonated
buVer (pH 7.4), gassed with 5% CO2/95% N2.
The exposed tissue was kept moist by covering
with saline soaked gauze to minimise heat loss
and fluid evaporation.
The animals were placed in a supine position
on a Plexiglas viewing stage in preparation for
microscopic observation; the mesentery was
mounted onto a Zeiss Axioskop FS (Zeiss,
Welwyn Garden City, UK) microscope stage. A
water immersion objective lens (magnification
×40; Zeiss) and an eyepiece (magnification
×40; Zeiss) were used to observe the microcir-
culation. The preparation was transilluminated
with a 12 V, 100 W halogen light source. A
Hitachi CCD colour camera (model KPC571
Tokyo, Japan) acquired images that were
displayed onto a Sony Triniton colour video
monitor (model PVM 144OQM) and recorded
onto a Sony super-VHS video cassette recorder
(model SVO-9500 MDP) for subsequent
oZine analysis. A video time-date generator
(FOR-A video timer, model VTG-33, Tokyo,
Japan) projected the time, date, and stopwatch
functions onto the monitor. Three to five
randomly selected postcapillary venules (diam-
eter 20–40 µm; length at least 100 µm) were
observed for each rat. The extent of the
inflammatory response elicited by IL-1â pre-
vented evaluation of the rolling phenomenon
with quantification of white blood cell velocity.
In contrast, adhesion could be easily monitored
by counting, for each vessel, the number of
adherent leucocytes in 100 µm length. Leuco-
cyte emigration from the microcirculation into
the tissue was quantified by counting the
number of cells that had emigrated out of the
vessel at up to 50 µm, 50–100 µm, and 100–150
µm away from the vessel wall in parallel with
100 µm vessel segments.
In some experiments the number of perito-
neal leucocytes was also monitored by staining
aliquots of the peritoneal lavage fluids (col-
lected by washing the cavities with 10 ml phos-
phate buVered saline (PBS)) with Turk’s solu-
tion (0.01% crystal violet in 3% acetic acid)
and counting cells under a light microscope.
DRUG TREATMENTS
Dexamethasone (sodium phosphate salt,
David Ball Laboratories, Warwick, UK) was
administered subcutaneously at 30 or 100
µg/kg one hour prior to IL-1â.16 The functional
role of endogenous ICAM-1 was assessed by
injecting 2 mg/kg intravenously of mouse anti-
rat ICAM-1 monoclonal antibody (clone
1A29) 30 minutes prior to challenge with 20 ng
rat IL-1â intraperitoneally; both dose and pro-
tocol of treatment have been validated in
several previous studies—for example, Zim-
merman et al.21 The potential functional role
for endogenous KC was determined by inject-
ing 2 mg intravenously of specific goat antirat
KC polyclonal antibody (a generous gift of Dr
John Zagorski, Oral Infection and Immunity
Branch, NIDR/NIH, Bethesda, Maryland,
USA) 30 minutes prior to challenge with the
cytokine.22 Control animals received identical
doses of non-immune mouse IgG or goat IgG
(Sigma Chemical Co., Poole, UK), respec-
tively.
WHOLE MOUNT PREPARATION OF MESENTERIES
TO DETECT ICAM-1 AND KC EXPRESSION
ICAM-1
As detection of endothelial antigens has been
successfully obtained following in vivo admin-
istration of the primary antibody (for example,
P-selectin23), rats were treated with an anti-
ICAM-1 monoclonal antibody (clone 1A29; 2
mg/kg intravenously) 10 minutes prior to tissue
collection. Animals were perfused through the
heart with 100 ml of 4% paraformaldehyde in
0.1 M PBS at room temperature. The mesen-
tery was then ligated and removed; the appro-
priate ileal section of the tissue was carefully
excised and pinned out onto Sylgard 184 elas-
tomer resin (BDH, Poole, UK) and postfixed
in the same fixative. Tissues were permeabi-
lised in graded ethanol and endogenous
peroxidases quenched with 1% H2O2 for 30
minutes. After thorough washing, whole
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mounts were incubated with normal horse
serum (1/100 in PBS + 0.1% low endotoxin
bovine serum albumin, globulin free) for one
hour to block non-specific binding sites for
IgGs.Mounts were then drained and incubated
with secondary preadsorbed biotinylated horse
antimouse IgG (Vectastain Elite ABC, Vector
Laboratories, Peterborough, UK) at 4°C over-
night. Following another washing step in PBS,
tissues were first incubated with ABC horse-
radish peroxidase complex (30 minutes) and
then with 0.05% 3,3'-diaminobenzidine tetra-
hydrochloride (Sigma Chemical Co.) in 0.05
M Tris buVer for colour development.
KC
In order to monitor KC expression, whole
mount preparations were prepared as above,
peroxidase blocked, and incubated in vitro with
normal goat serum (1/66.7 in PBS + 0.1% low
endotoxin bovine serum albumin, globulin free)
to block non-specific binding sites for IgGs. Tis-
sues were then incubated overnight at 4°C with
a rabbit antirat KC polyclonal antibody (0.5
µg/ml; gift of Dr K Watanabe, Institute for
Cytosignal Research, Tokyo, Japan). The re-
mainder of the experiment was as above, with
the exception that a goat antirabbit IgG was
used as secondary antibody (Vectastain Elite
ABC, Vector Laboratories, Peterborough, UK).
In all cases, preparations were treated
according to the strict protocol outlined above
to reduce possible variabilities between the
whole mounts. All tissues were counterstained
with haematoxylin and mounted with an aque-
ous mounting medium.
MEASUREMENT OF ENDOTHELIAL ICAM-1
EXPRESSION BY IN VIVO DUAL RADIOLABELLING
Mouse antirat ICAM-1 monoclonal antibody
(clone 1A29) and clone P-23 (a non-binding
murine IgG directed against human P-selectin,
used as internal control) were labelled with 125I
and 131I, respectively by an established
method.24 25 Rats were injected intraperito-
neally with 20 ng IL-1â, and two or four hours
later were anaesthetised with 100 mg/kg intra-
peritoneal Inactin, and the right carotid artery
and jugular vein were cannulated.Amixture of 4
µg 125I-ICAM-1 monoclonal antibody, 5 µg
131I-non-binding monoclonal antibody (P-23),
and 246 µg unlabelled ICAM-1 monoclonal
antibody was administered via the jugular vein
catheter. After five minutes, blood samples were
obtained through the carotid artery. Animals
were exsanguinated by vascular perfusion with
sodium bicarbonate buVer via the jugular vein
with simultaneous blood withdrawal via the
carotid artery. The inferior vena cava was
severed and the animal constantly perfused with
sodium bicarbonate buVer via the carotid artery
until all blood was flushed. To calculate
ICAM-1 expression, 125I (binding antibody) and
131I (non-binding antibody) activities in each
organ or tissue and in a 50 µl plasma sample
were estimated using a Cobra II gamma counter
(Packard, Meriden, Australia), with automatic
correction for background activity and spillover.
The total radioactivity injected in each experi-
ment was also calculated by counting a 5 µl
sample of the mixture containing the radiola-
belled monoclonal antibodies. The accumulated
activity of each monoclonal antibody in a select
organ was expressed as the percentage of the
injected dose (% ID) per g of wet tissue. The
formula used to calculate ICAM-1 expression
was as follows: ICAM-1 expression = (% ID/g
for 125I) − (% ID/g for 131I) × (% ID 125I in
plasma)/(% ID in 131I plasma).
Table 1 EVect of dexamethasone (DEX) on interleukin
(IL) 1â induced leucocyte extravasation into the rat
peritoneal cavity
Leucocytes
Treatment Time (h) 106 per rat %
None 0 0.97 (0.06) 100
IL-1â 2 1.48 (0.27) 152
+ DEX 2 1.22 (0.17) 126
IL-1â 4 3.10 (0.25)* 319
+ DEX 4 1.10 (0.29)† 113
Rats were left untreated or injected intraperitoneally with 20 ng
rat IL-1â. In some cases animals were pretreated with DEX (100
µg/kg subcutaneously) one hour prior to cytokine administration.
Data are mean (SEM); n=6 rats per group.
*p<0.05 versus control group (time 0); †p<0.05 versus respec-
tive IL-1â group (time 4 h).
Figure 1 EVect of dexamethasone (DEX) on interleukin (IL) 1â induced leucocyte
adhesion and emigration in rat mesenteric postcapillary venules. Data are mean (SEM);
n=6 rats. *p<0.05 v respective IL-1â group.
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ELISA FOR KC DETECTION
The amounts of the KC chemokine in cell free
peritoneal lavage fluids were quantified using a
murine KC ELISA (R&D, Oxon, UK). A
standard curve with rat synthetic KC (gift of
Dr K Watanabe, Institute for Cytosignal
Research, Tokyo, Japan)26 was constructed
(concentration range 1–1000 pg/ml) and com-
pared with that of murine KC (furnished by the
manufacturer): 100% cross reactivity with rat
KC was found. Data are reported as pg of rat
KC per cavity.
STATISTICS
Data are reported as mean (SEM) of the
number of rats per group. Statistical differences
were assessed by one way analysis of variance
followed by the Bonferroni test for intergroup
comparisons. A value of p<0.05 was taken as
significant.
Results
EFFECT OF DEXAMETHASONE
Intraperitoneal injection of IL-1â caused a gen-
eralised inflammatory response with an increase
in the number of adherent cells at two hours
(fourfold) and four hours (fivefold) above that of
saline treated animals (fig 1A). Pretreatment
with DEX one hour prior to cytokine adminis-
tration caused a dose dependent decrease in the
number of adherent cells at the two hour time
point which reached significance only at the 100
µg/kg dose. The inhibitory eVect of DEX on
IL-1â induced cell adhesion was slightly greater
at the four hour time point (approx. 60%; fig
lA). IL-1â caused an increase in the number of
emigrated cells outside the postcapillary venule
at two and four hours. As expected, the number
of emigrated cells was lower in the zones further
away from the postcapillary wall (fig 1B). In
Figure 2 Involvement of intercellular adhesion molecule (ICAM) 1 in interleukin (IL) 1â
induced cell adhesion and emigration. (A) Animals were treated with 2 mg/kg mouse IgG or
mouse antirat ICAM-1 monoclonal antibody one hour prior to IL-1â administration (20 ng
intraperitoneally).Mesenteries were exposed two hours later, and the degree of cell adhesion
(per 100 µm vessel wall) and emigration quantified by videomicroscopy.Data are mean
(SEM); n=6 rats. *p<0.05 v mouse IgG group. (B) ICAM-1 expression in the mesenteric
tissue as assessed by the dual antibody technique.Rats were treated with rat IL-1â (20 ng
intraperitoneally) and some of them pretreated with dexamethasone (DEX) one hour prior to
the cytokine.At the reported times post-IL-1â, the specific radioactivity due to endogenous
ICAM-1 was determined.Data are mean (SEM); n=5 rats per group. *p<0.05 v control
group (time 0); †p<0.05 v IL-1â group (time 4 h).
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Figure 3 Localisation of intercellular adhesion molecule
(ICAM) 1 immunostaining in inflamed rat mesenteric
postcapillary venules. Typical micrographs of the ileal section
of rat mesentery whole mounts. (A) Preparations excised two
hours post-administration of 20 ng rat interleukin (IL) 1â
from an animal injected with control mouse IgG 10 minutes
prior to sacrifice. (B) As for A, but the rat was injected with
2 mg/kg mouse antirat ICAM-1 10 minutes prior to
sacrifice and tissue collection.Note the brown staining
around the endothelium of the postcapillary venule. (C) As
in B, but the rat was treated with 100 µg/kg subcutaneous
dexamethasone one hour prior to intraperitoneal injection of
IL-1â.Note the scarce brown immunostaining compared
with B. Pictures are representative of five distinct
preparations. L, vessel lumen. Bar, 30 µm.
708 Tailor, Tomlinson, Salas, et al
 group.bmj.com on April 4, 2011 - Published by gut.bmj.comDownloaded from 
contrast to cell adhesion, the lower dose of 30
µg/kg DEX inhibited cell emigration at two
hours (50%;fig 1B). Similarly, the higher dose of
100 µg/kg caused a greater inhibition in the
number of emigrated cells (approximately 80%
reduction). With either dose of DEX the
number of emigrated cells was significantly
reduced in all fields measured. No diVerence in
the number of cells collected from the peritoneal
cavity was seen at two hours post-IL-1â whereas
a significant increase was measured in the IL-1â
group at the four hour time point (table 1). This
eVect was also abolished by treatment with 100
µg/kg DEX.
ROLE OF ENDOGENOUS ICAM-1 AND THE EFFECT
OF DEXAMETHASONE
Passive immunisation of rats against ICAM-1
provoked a remarkable inhibition of IL-1â
induced leucocyte adhesion (90% reduction)
and emigration (>80% reduction), as assessed at
the two hour time point (n=6, p<0.05; fig 2A).A
notable immunostaining for ICAM-1 was asso-
ciated with the endothelium in whole mounts of
postcapillary venules inflamed with IL-1â (fig
3B); this was not seen in control tissues (where
rats were treated intravenously with mouse IgG)
(fig 3A).Treatment of rats with DEX (100 µg/kg
subcutaneously, one hour) reduced the intensity
of the immunostaining associated with the
inflamed vessels (fig 3C).
To quantify the latter observation, the dual
antibody technique was used. Figure 2B shows
the increased radioactivity associated with the
mesenteries at two and four hours post-IL-1â
injection. As statistical significance was
reached at four hours post-IL-1â, the eVect of
DEX was tested only at this time point. Treat-
ment of rats with DEX produced a significant
reduction in IL-1â induced ICAM-1 expres-
sion only at the highest dose tested, that is, 100
µg/kg (>70% inhibition if calculated on the net
values, when the basal level was subtracted;
n=4, p<0.05; fig 2B). The glucocorticoid hor-
mone did not aVect basal (constitutive) expres-
sion of ICAM-1 when injected in control rats
(data not shown). Table 2 reports the dual
eVect of IL-1â and DEX on ICAM-1 expres-
sion in several organs of the peritoneal cavity.
High constitutive ICAM-1 was found in the
liver, with lowest values being measured in
stomach, pancreas, and distal colon. Intraperi-
toneal injection of IL-1â induced ICAM-1
expression in a time dependent fashion in all
organs tested except stomach, caecum, and
distal colon. The highest increment was seen in
the pancreas (+88%), followed by the liver
(+45%), ileum (+57%), and jejunum (+47%)
(table 2). Treatment of rats with the highest
dose of DEX prevented IL-1â induced
ICAM-1 induction in most organs except the
jejunum. At the lower dose of 30 µg/kg, DEX
was found to be inhibitory only in the liver.
Table 2 EVect of dexamethasone (DEX) and intercellular adhesion molecule (ICAM) 1 expression in several abdominal
organs after administration of interleukin (IL) 1â
Treatment
(h post IL-1â) Liver Pancreas Stomach Jejunum Ileum Caecum Distal colon
Control (0) 2.99 (0.15) 0.09 (0.01) 0.09 (0.01) 0.15 (0.02) 0.14 (0.02) 0.12 (0.01) 0.09 (0.01)
IL-1â (2) 3.83 (0.27) 0.13 (0.01) 0.10 (0.01) 0.19 (0.01) 0.19 (0.01) 0.20 (0.02) 0.12 (0.01)
IL-1â (4) 4.28 (0.41)* 0.17 (0.02)* 0.11 (0.01) 0.22 (0.03)* 0.22 (0.03)* 0.16 (0.01) 0.12 (0.01)
+ 30 µg/kg DEX (4) 3.23 (0.21)† 0.20 (0.02) 0.12 (0.02) 0.29 (0.04) 0.22 (0.40) 0.18 (0.02) 0.13 (0.02)
+ 100 µg/kg DEX (4) 3.30 (0.20)† 0.13 (0.01) 0.09 (0.01) 0.19 (0.03) 0.15 (0.01)† 0.16 (0.01) 0.10 (0.01)
Rats (n=5) were left untreated (control group) or were injected intraperitoneally with 20 ng rat IL-1â at time 0. Other animals
received DEX at the reported doses subcutaneously one hour prior to IL-1â. Data (mean (SEM)) are reported as percentage of
injected dose/g wet tissue.
*p<0.05 versus control group (time 0); †p<0.05 versus IL-1â group (4 h).
Figure 4 Involvement of KC in interleukin (IL) 1â
induced cell adhesion and emigration. (A) Animals were
treated with 2 mg goat IgG or goat antirat rat KC polyclonal
antibody one hour prior to IL-1â administration (20 ng
intraperitoneally).Mesenteries were exposed two hours later,
and the degree of cell adhesion (per 100 µm vessel wall) and
emigration quantified by videomicroscopy.Data are mean
(SEM); n=8 rats. *p<0.05 v mouse IgG group. (B)
Detection of rat KC protein in the peritoneal cell free lavage
fluids of control rats (n=4), rats injected with IL-1â (20 ng
intraperitoneally; n=5), and animals pretreated with
dexamethasone (DEX) one hour prior to IL-1â
administration (n=5).Lavage fluids were collected two hours
post-IL-1â.Data are mean (SEM). *p<0.05 v IL-1â
group.
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ROLE OF ENDOGENOUS KC AND THE EFFECT OF
DEXAMETHASONE
The in vivo administration of anti-KC polyclo-
nal antibody produced a fourfold reduction in
IL-1â induced cell adhesion and emigration in
the rat mesenteries at two hours as quantified
by intravital microscopy (n=8, p<0.05; fig 4A).
To visualise the presence of endogenous KC
after IL-1â administration, mesenteries were
immunostained with a specific anti-KC rabbit
serum. Figure 5B shows the intense immuno-
staining found in perivenular mast cells which
was absent in the inflamed tissue stained with
normal goat serum (fig 5A). In some cases KC
positivity seems to be associated with the gran-
ules which have been released from the
activated mast cell (fig 5B). Treatment of rats
with DEX (100 µg/kg subcutaneously) reduced
KC immunostaining (fig 5C). To substantiate
these observations in a quantitative manner,
the release of KC protein in the peritoneal lav-
age fluids was also monitored. Figure 4B shows
that KC immunoreactivity was not detected in
saline injected rats (control), whereas a notable
release was measured two hours post-IL-1â
injection. This was almost completely abro-
gated by 100 µg/kg DEX (n=5, p<0.05; fig 4B).
Discussion
In this study we showed for the first time that
endothelial ICAM-1 and mast cell derived KC
mediate IL-1â induced cell adhesion to in-
flamed postcapillary venules in the gut.We also
showed that the inhibitory eVect of DEX on
these parameters is functionally linked to a
reduction of leucocyte adhesion to these
vessels.
Intraperitoneal injection of IL-1â produced
an intense local inflammatory response which
was essentially maximal at the two hour time
point when monitored by videomicroscopy.
This technique has been previously used to
characterise the molecular determinants in-
volved in this response. A functional role for
endothelial platelet-endothelial cell adhesion
molecule 1 (CD31) and platelet activating fac-
tor in the IL-1â induced cell emigration, but
not cell adhesion, process induced by IL-1â has
been reported previously.10 27 No studies have
addressed the nature of the mediators respon-
sible for IL-1â induced leucocyte adhesion.
Among several potential candidates, we fo-
cused on ICAM-1 (CD54) for the following
reasons: it is induced in vitro by IL-1â28; it is
functionally related to IL-1â induced neutro-
phil transendothelial migration in vitro29 30; and
a neutralising monoclonal antibody antirat
ICAM-1 well characterised in in vivo systems
was available.21 We found that IL-1â induced
leucocyte adhesion in vivo is largely dependent
on ICAM-1. As expected, an intense expres-
sion of this adhesion molecule on the postcap-
illary endothelium of rat mesenteries exposed
to IL-1â was seen by immunohistochemical
analysis.
Among other mediators, glucocorticoid hor-
mones also target adhesion molecules to inhibit
the interaction between leucocytes and en-
dothelium. Until now, this has been mainly
shown in vitro; the pioneering study of
Cronstein et al 31 reported DEX inhibition of
ICAM-1 and E selectin (CD62E) expression
on activated endothelial cells. This eVect of
DEX has been functionally related to cell
adhesion31 and emigration32 as assessed under
flow conditions in vitro. Few studies have
investigated the eVects of DEX on adhesion
molecule expression in vivo. Suzuki et al23
showed endogenous glucocorticoid hormones
to control P selectin expression in rat me-
senteric postcapillary venules. Here, we have
initially confirmed the dose dependency for
DEX inhibition of IL-1â induced cell adhesion
such that a dose of 100 µg/kg was required to
reduce this parameter (whereas a significant
inhibition of IL-1â induced cell emigration was
seen at a dose of 30 µg/kg).16 Treatment of rats
with 100 µg/kg DEX seemed to reduce the
extent of ICAM-1 immunostaining observed
Figure 5 Localisation of KC immunostaining in inflamed
rat mesenteric postcapillary venules. Typical micrographs of
the ileal section of rat mesentery whole mounts. (A)
Preparations excised two hours after administration of 20
ng rat interleukin (IL) 1â and incubated with non-specific
rabbit IgG. Arrowheads indicate some of the perivenular
mast cells. (B) As in A, but the tissue was incubated with
specific rabbit antirat KC IgG.Arrowheads indicate some
of the perivenular mast cells which stained for KC. (C) As
in B, but the rat was treated with 100 µg/kg subcutaneous
dexamethasone one hour prior to intraperitoneal injection of
IL-1â. Arrowheads indicate some of the perivenular mast
cells which appeared less stained for KC when compared
with B. Pictures are representative of four distinct
preparations. L, vessel lumen. Bar, 25 µm.
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on the activated postcapillary venule. This
observation was substantiated in a quantitative
manner by the experiments with radiolabelled
antibodies. The dual antibody radiolabelling
technique has been recently refined and used
to measure endothelial ICAM-1 expression in
large vascular beds and organs following
animal treatment with lipopolysaccharide or
tumour necrosis factor á.24 33 In our case a basal
expression of ICAM-1 was detected in inacti-
vated rat mesenteries, and values were in-
creased following IL-1â injection to reach sta-
tistical significance at four hours postinjection.
The eVect of DEX was then assessed at this
time point as an almost identical inhibition of
IL-1â induced cell adhesion was seen by
videomicroscopy at two and four hours post-
IL-1â. In keeping with the functional data, a
significant attenuation of anti-ICAM-1 mono-
clonal antibody binding associated with the rat
mesenteries was measured only after adminis-
tration of the antiadhesive dose of DEX (100
µg/kg). Overall these data indicate that: IL-1â
induces ICAM-1 on the postcapillary endothe-
lium of rat mesenteries and this is functionally
linked to leucocyte adhesion (and emigration
in view of the sequential relation between these
events); and treatment of rats with 100 µg/kg
DEX can prevent induction of this adhesion
molecule which is correlated with its inhibitory
eVect on cell adhesion.
The CXC chemokine KC is a potent neutro-
phil activator in vitro,34 35 and recruits leucocytes
on the endothelium of postcapillary venules
once superfused on rat mesenteries.36 The link
between KC and IL-1â, however, has been
mainly investigated in in vitro studies, reporting
the clear ability of the cytokine to induce KC
expression and release.20 37 We now show that
endogenous KC mediates IL-1â induced cell
adhesion to the activated mesenteric endothe-
lium in vivo using a polyclonal antibody
validated in a rat model of peritonitis.22 A similar
degree of inhibition (70–90%) of IL-1â induced
leucocyte adhesion and emigration was obtained
with the anti-ICAM-1 monoclonal antibody or
with the anti-KC polyclonal antibody; this indi-
cates that there is a clear redundancy of media-
tors which are activated by the cytokine to pro-
mote the sticking of rolling leucocytes, or that
the expression and/or function of these two
mediators is somehow linked. There are no
reports that KC can induce ICAM-1 protein
expression, but as the chemokine can upregulate
ICAM-1 ligand (the â2 integrin complex ex-
posed on the leucocyte cell surface)38 the latter
hypothesis seems plausible.
The immunohistochemical analysis showed
KC expression to be associated with perivenu-
lar mast cells, tissue dwelling leucocytes which
play a central role in initiation of the host
inflammatory response.39 The identity of this
cell type was also confirmed by the classical
metachromatic staining of the granules with
toluidine blue (not shown). To our knowledge
this is the first study which shows KC (or any
other chemokine) association with mast cells in
experimental inflammation in vivo. Until now,
few in vitro studies have shown the ability of
mast cells to produce chemokines, although
there is evidence that a human mast cell
leukaemia line can express multiple chemokine
genes40 and that interleukin 8 is then stored in
granules and released on activation.41
Treatment of rats with DEX seemed to
reduce the extent of KC immunostaining
observed in perivenular mast cells. These
qualitative observations were reinforced by the
ELISA experiments. Rat KC protein was not
detected in the lavage fluids of control rats, but
it increased two hours after local administra-
tion of IL-1â. This eVect was essentially abro-
gated by DEX. It has been previously reported
that DEX is able to prevent rat KC gene
expression20 through an impairment of nuclear
factor KB activation.42 In addition, glucocorti-
coid hormone inhibition of this nuclear factor
is also at the basis of the negative eVect on
ICAM-1 upregulation in in vitro experiments.43
It is very likely that similar molecular mecha-
nisms are operating in our experimental condi-
tions in vivo. If this hypothesis is confirmed in
future studies, we would then know that a dose
of 100 µg/kg DEX has to be used experimen-
tally to aVect nuclear factor KB mediated
events in vivo. These observations add KC to
the list of chemokines, including macrophage
inflammatory protein lá or monocyte chemoat-
tractant protein 144 aVected by in vivo treat-
ment with DEX, a feature, however, which is
not shared by all chemokines.45
To conclude, glucocorticoid hormones are
potent anti-inflammatory drugs which are
widely used in several pathologies of the
bowel.46 Here we have used an experimental
model relevant to these pathologies in view of
the central role played by IL-1â11 13 and
confirmed an eVect of DEX on the leucocyte
extravasation process activated by this cyto-
kine. We cannot exclude that other adhesion
molecules and/or chemokines might be in-
volved in the antiadhesive eVect of DEX,
although with these doses and protocol of
treatment we can certainly eliminate an eVect
of the glucocorticoid hormones on expression
of leucocyte adhesion molecules.45 47 Using a
series of in vitro and in vivo assays, we show
that inhibition of ICAM-1 and KC expression
and/or release is at least one of the basic
mechanisms responsible for a major therapeu-
tic action of glucocorticoid hormones, which is
the inhibition of leucocyte infiltration into
injured tissues.
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